Protocol Ledger

NCT06962865 · Phase II · RECRUITING

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Interventional Phase II clinical trial protocol NCT06962865 sponsored by RemeGen Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-30 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06962865
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06962865
Protocol FieldVerified Registry Value
NCT IdentifierNCT06962865
Consolidated Lead SponsorRemeGen Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2025-06-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06962865
Hospital Research SiteLocationSite Profile
Jilin Cancer HospitalChangchun, ChinaOpen Hospital Dossier ->
The Second Xiangya Hospital of Central South UniversityChangsha, ChinaOpen Hospital Dossier ->
Sichuan Cancer HospitalChengdu, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI